Find Academic Supervisors

• Pharmacology
• Receptor Pharmacology
• Experimental Oncology
• +4 more

Gabor Halmos is a University Professor at the University of Debrecen, where he serves as Head of the Department of Biopharmacy and Vice Dean. His extensive academic career spans over three decades with 212 scientific publications to his name, demonstrating his significant contributions to pharmacology and oncology research. His work appears in top-tier journals with 36.8% of his publications classified in Q1/D1 categories according to SCImago metrics. Professor Halmos specializes in receptor pharmacology and experimental oncology, with particular expertise in kidney cancer, uveal melanoma, and growth hormone-related signaling pathways. His research focuses on identifying novel biomarkers, studying molecular mechanisms in renal cell carcinoma, and developing targeted cancer therapies using natural compounds like quercetin. His work bridges pharmaceutical sciences with clinical oncology, aiming to translate laboratory findings into improved cancer treatments. The Department of Biopharmacy under his leadership maintains strong research output with significant international collaborations. Analysis of his recent publications (2023-2025) reveals a strong focus on molecular oncology, particularly in kidney cancer research where he investigates microRNA expression patterns, angiogenesis markers, and tumor biomarkers like IDO and PTEN. His collaborative work with international researchers, including Schally Andrew Victor (198 co-authored papers), demonstrates his significant standing in the field of receptor pharmacology and cancer therapeutics. His research spans multiple high-impact categories including Oncology (70 publications), Medicine (106), and Biochemistry, Genetics and Molecular Biology (93). Medicine (106 publications) Oncology (70 publications) Biochemistry, Genetics and Molecular Biology (93 publications) Pharmacology, Toxicology and Pharmaceutics (21 publications) As Head of Department and Vice Dean, Professor Halmos mentors numerous students and researchers while leading his research team in investigating novel therapeutic approaches for various cancers. His laboratory focuses particularly on molecular pathways in renal cell carcinoma and melanoma, with emphasis on identifying potential targets for intervention and developing natural compound-based therapies. His ongoing research continues to contribute significantly to the understanding of cancer biology and potential therapeutic interventions.

• Molecular Biology
• Genetics
• Cancer Research
• +5 more

Alex Nigg is an active Researcher in the Department of Pathology at Erasmus MC, with a robust publication record spanning molecular biology, cancer research, and immunology. Their work demonstrates significant contributions to understanding nucleosome dynamics, tumor progression mechanisms, and lipid metabolism in disease contexts. Research interests focus on the intersection of molecular biology and pathology, particularly examining how chromatin remodeling influences cancer development and immune responses. Nigg's work bridges basic science with clinical applications, especially in oral cancer, melanoma, and pancreatic cancer models. Their research employs advanced techniques including live-cell imaging, bioluminescence tracking, and lipidomic profiling to uncover novel disease mechanisms. Recent publications reveal a strong trend toward interdisciplinary approaches, combining molecular biology with computational methods and imaging technologies. The research spans cancer biology, immunology, and metabolic pathways, with particular emphasis on how epigenetic regulation and microRNA networks influence tumor progression and therapeutic responses. Nigg's work shows increasing focus on translational applications, particularly in developing diagnostic tools for cancer detection and monitoring immune responses. Nigg has established productive collaborations across multiple institutions, as evidenced by co-authorship on diverse research projects. Their work has garnered attention in academic circles with citations across multiple publications and readership on academic platforms. The research output demonstrates consistent productivity with multiple high-impact publications appearing in leading journals across pathology, oncology, and molecular biology fields.

• Toxicology
• Hepatotoxicity
• Drug-Induced Liver Injury (DILI)
• +5 more

Dr. Wiebke Albrecht is a Scientific Associate in Systems Toxicology at the Leibniz Research Centre for Working Environment and Human Factors (IfADo) in Dortmund, Germany, affiliated with Technical University of Dortmund. She works under Prof. Dr. Jan G. Hengstler's leadership with contact information listed as +49 231 1084-431 and albrecht@ifado.de. Her research focuses on hepatotoxicity prediction, drug-induced liver injury mechanisms, and development of in vitro testing methodologies for toxicological assessment. Dr. Albrecht's research interests center on systems toxicology approaches to understanding hepatotoxicity mechanisms. She investigates drug-induced liver injury (DILI), develops predictive models for toxicological risk assessment, and studies interspecies differences in toxin metabolism. Her work integrates experimental toxicology with computational approaches to improve in vitro testing systems' accuracy and reliability. Specific areas include bile acid effects on cytotoxicity, steatosis prediction methods, and gene expression analysis for toxicity classification. Analysis of Dr. Albrecht's publication trends reveals consistent focus on improving hepatotoxicity prediction methods and understanding liver injury mechanisms. Her work spans from fundamental research on toxin metabolism across species to developing practical testing protocols. A notable trend is integrating high-throughput gene expression data with traditional cytotoxicity assays to create robust predictive models. Her research addresses critical challenges like interspecies extrapolation, concentration optimization for in vitro testing, and developing human-relevant liver toxicity models. Dr. Albrecht actively participates in numerous collaborative research projects, working with scientists across German institutions and internationally. Her extensive publication record suggests substantial research funding support, though specific grant details aren't provided in the text. She contributes significantly to the EU-ToxRisk project as evidenced by her 2020 publication on method documentation for regulatory use of new approach methods. As part of the Systems Toxicology team at IfADo, Dr. Albrecht utilizes advanced methodologies including intravital imaging, HPLC-MS/MS analysis, and computational modeling. The institute's facilities include animal laboratories, bioanalytical units, and outpatient departments that support her research on hepatotoxicity mechanisms and prediction methods.

• Toxicology
• Intravital Toxicology
• Pharmacology
• +7 more

Prof. Dr. Ahmed Ghallab is Professor of Toxicology at the Faculty of Veterinary Medicine, South Valley University, Egypt, and Head of the Intravital Toxicology Research Group at the Leibniz Research Centre for Working Environment and Human Factors (IfADo) in Dortmund, Germany. His dual appointments reflect his interdisciplinary work bridging veterinary and human toxicology. Dr. Ghallab earned his Dr. med. vet. from Justus-Liebig-University Gießen in 2013, following a Master's degree (2009) and Bachelor's degree (2006) in Veterinary Medicine from South Valley University. His career progressed from postdoctoral scientist at IfADo (2013) to BMBF-funded Junior Group Leader (2015-2021), Assistant Professor (2018), and finally Professor (2023). His research focuses on intravital toxicology , particularly bile acid metabolism , drug-induced liver injury , and hepatobiliary system pathophysiology. He employs intravital imaging , computational modeling , and molecular techniques to investigate liver-kidney axis interactions, cholestatic diseases, and mechanisms of hepatotoxicity. Analysis of his recent publications (2022-2025) reveals a strong emphasis on bile acid transporters , cholemic nephropathy , liver regeneration , and hepatocellular carcinoma development. His work spans from basic molecular mechanisms to translational applications, including development of novel diagnostic probes and therapeutic strategies targeting bile acid pathways. Dr. Ghallab leads the Intravital Toxicology Research Group at IfADo, where his team conducts cutting-edge research using advanced imaging techniques to study real-time toxicological processes in living organisms. His work has significant implications for understanding drug safety, environmental toxicants, and metabolic diseases affecting the liver and related organ systems.

• Cartilage
• Joint Disease
• Stem Cells
• +7 more

Lise Charlotte Berg, DVM, PhD, is an Associate Professor at the Department of Veterinary Clinical Sciences within the Faculty of Health and Medical Sciences at the University of Copenhagen. She is based at the large animal facility and hospital in Tåstrup, where her research labs are strategically located in close proximity to clinical areas, facilitating direct translation of research findings to clinical practice. Her work bridges veterinary clinical science with molecular orthopaedics, focusing on equine health and performance. Dr. Berg earned her Doctor of Veterinary Medicine from the University of Copenhagen (1996-2002), followed by a PhD in Veterinary Biochemistry from the same institution (2004-2008). During her doctoral studies, she conducted research at the University of Guelph, Canada, and has maintained international collaborations throughout her career, including a significant period as a visiting researcher at Cornell University under Dr. Lisa A. Fortier. Her research program centers on equine molecular orthopaedics with particular emphasis on cartilage biology, joint disease mechanisms, stem cell therapies, and regenerative medicine applications for sport horses. Dr. Berg leads the Equine Molecular Orthopaedics research group, which investigates cellular and molecular mechanisms underlying orthopaedic conditions in horses and develops innovative therapeutic approaches. Her work often integrates laboratory science with direct clinical applications to address pressing challenges in equine medicine. Dr. Berg's publication record demonstrates consistent focus on translational research in equine orthopaedics, with recent work emphasizing stem cell therapies for osteoarthritis, molecular biomarkers in joint disease, and performance-related issues in athletic horses. Her research combines advanced molecular techniques with clinical validation to develop practical solutions for equine health problems. EliteForsk Diplom (rejsestipendium) - January 25, 2007 ICRS (International Cartilage Repair Society) Meeting - Certificate of Merit As principal investigator on multiple research projects, including significant funding from the Danish Research Council, Dr. Berg has secured over 9.4 million DKK in research funding. She actively participates in academic service as a reviewer for major journals in veterinary and orthopaedic research and has served on PhD assessment committees at multiple international institutions including universities in Copenhagen, Oslo, and Ghent. The Equine Molecular Orthopaedics research group led by Dr. Berg operates at the intersection of basic science and clinical application. The group's work benefits from direct access to clinical cases at the university hospital, allowing for rapid translation of laboratory findings to patient care. Current projects focus on optimizing cell-based therapies for joint disorders and understanding the molecular basis of athletic performance limitations in sport horses.

• Motor Control
• Neuroscience
• Rehabilitation Science
• +4 more

Jessica Pingel is an Associate Professor in the Department of Neuroscience within the Faculty of Health and Medical Sciences at the University of Copenhagen, specializing in motor control research. Her work bridges neuroscience and rehabilitation science with a focus on movement disorders and therapeutic interventions. Her research interests center on motor control mechanisms in neurological conditions, particularly cerebral palsy, stroke, and spinal cord injury. She investigates biomechanical, physiological, and molecular aspects of muscle function using advanced techniques like synchrotron imaging, ultrasound, and molecular analysis. Her work extends to adaptive sports such as frame running and therapeutic exercise protocols for neurological rehabilitation. Analysis of her recent publications (2022-2024) reveals three dominant research trajectories: (1) Cerebral palsy rehabilitation through frame running capacity studies and molecular biomarker analysis, (2) Advanced imaging of neuromuscular tissue atrophy in stroke/SCI, and (3) Methodological innovations in muscle measurement techniques and academic supervision models. Her interdisciplinary approach integrates human and animal models with clinical applications. Dr. Pingel actively supervises master's thesis students as evidenced by her publication on optimized supervision models. She participates in major research forums including the European Muscle Conference and is affiliated with the Nielsen Lab at the University of Copenhagen, where she contributes to translational neuroscience research.

• Computational Pharmacology
• Bioinformatics
• Structural Biology
• +2 more

Jimmy Caroli serves as an Assistant Professor in the Department of Drug Design and Pharmacology at the University of Copenhagen. His research in Pharmaceutical Informatics centers on computational approaches for drug design, with a focus on G protein-coupled receptors (GPCRs) and pharmacogenomics. He develops key bioinformatics resources including GPCRdb, GproteinDb, and PGxDB. His primary research interests include computational pharmacology, bioinformatics, structural biology of receptors, pharmacogenomics, and drug design. He applies advanced computational techniques such as AlphaFold2 for modeling receptor structures and signaling pathways. His work aims to bridge the gap between molecular structure and therapeutic applications, facilitating drug discovery and personalized medicine. Analysis of his recent publications reveals a consistent focus on database development and structural modeling for GPCRs. He has pioneered resources for biased signaling and pharmacogenomics, integrating machine learning and high-performance computing. His tools support the global research community in understanding receptor pharmacology and genetic factors in drug response.

Crystal M. WeymanView profile

Professor

• Cell Signaling
• Molecular Biology
• Muscle Differentiation
• +4 more

Dr. Crystal M. Weyman is a Professor and Chair of the Biological, Geological and Environmental Sciences Department at Cleveland State University's College of Arts and Sciences. She serves on the Planning Committee for the Center for Gene Regulation in Health and Disease (GRHD) and is listed as Regular and Research Faculty for GRHD. Her office is located in Science and Research Building, Room 266. Dr. Weyman's research focuses on understanding the signaling pathways that coordinately regulate the mutually exclusive biological endpoints of differentiation and apoptosis (programmed cell death) in skeletal myoblasts. Her laboratory also investigates signaling by oncogenic Ras. Dissecting this coordinate regulation could enable selective manipulation relevant to the amelioration of disease states associated with muscle degeneration and to the effectiveness of any treatment utilizing skeletal myoblast transfer. Analysis of Dr. Weyman's publications reveals a consistent research trajectory spanning over three decades, with a primary focus on skeletal myoblast differentiation, apoptosis regulation, and oncogenic Ras signaling. Her work demonstrates increasing sophistication in molecular techniques, with recent publications focusing on microRNA regulation, transcriptional control mechanisms involving MyoD and p53, and the role of specific proteins like PUMA in apoptosis pathways. Her research has broad implications for understanding muscle degeneration diseases and cancer biology. Dr. Weyman leads an active research laboratory with several PhD students and post-doctoral fellows. She has secured research funding that supports her laboratory's work, though specific grant details are not provided in the available information. Her collaborative approach is evident through her numerous co-authored publications with researchers across multiple institutions. Her laboratory team includes Dr. Jane Yoder Hill (Post-doctoral fellow), Fatima Said (PhD Student), Bryce Waldal (PhD Student), and Ara Mendez (PhD Student), who work together on projects related to skeletal myoblast differentiation and apoptosis pathways.

Girish ShuklaView profile

Professor

• Molecular Biology
• RNA Biology
• Gene Expression Regulation
• +7 more

Dr. Girish Shukla is a Professor at Cleveland State University affiliated with the Center for Gene Regulation in Health and Disease (GRHD), focusing on molecular mechanisms of eukaryotic gene expression at the RNA level. His research spans RNA biology, cancer therapeutics, and gene regulation. His primary research interests include: Molecular mechanisms of eukaryotic gene expression at the RNA level Noncoding RNAs and their regulatory roles Nuclear pre-mRNA splicing and minor spliceosome dynamics RNA:RNA and RNA:Protein interactions Post-transcriptional control in prostate cancer miRNA-mediated androgen receptor regulation Steroid biosynthesis pathways as cancer therapeutic targets Analysis of Dr. Shukla's recent publications reveals a strong emphasis on microRNA regulation in prostate cancer progression, with significant work on androgen receptor control mechanisms. His research increasingly integrates computational biology with molecular approaches to identify cancer biomarkers and therapeutic targets, particularly in RNA metabolism and noncoding RNA functions. The publications demonstrate consistent contributions to understanding spliceosomal mechanisms and their dysregulation in hematological cancers. Dr. Shukla actively mentors graduate researchers, including PhD student Asmita Bhattarai, within the GRHD center's collaborative environment. His laboratory employs cutting-edge molecular, biochemical, and computational tools to investigate RNA-protein interactions and splicing mechanisms. The Center for Gene Regulation in Health and Disease provides infrastructure for interdisciplinary research through its CSU/Cleveland Clinic Joint Ph.D. Programs and shared instrumentation facilities.

• Reproductive Biology
• Molecular Biology of Pregnancy
• Embryo-Maternal Communication
• +3 more

Monika M. KACZMAREK is an Associate Professor and Head of the Programming of Fertility and Development Scientific Group at the Institute of Animal Reproduction and Food Research of the Polish Academy of Sciences in Olsztyn, Poland. She leads the Laboratory of Molecular Biology and has established herself as a prominent researcher in reproductive biology with a focus on porcine models. Dr. KACZMAREK's research primarily centers on embryo-maternal communication, particularly the role of extracellular vesicles and microRNAs during early pregnancy. She investigates molecular mechanisms of implantation, endometrial biology, and follicular development in pigs, with significant contributions to understanding miRNA regulation in reproductive processes. Her work bridges basic molecular biology with practical applications in animal reproduction. Analysis of her recent publications reveals a strong focus on extracellular vesicle-mediated communication between embryo and endometrium, miRNA regulation in early pregnancy, and molecular responses to reproductive challenges. Her research spans reproductive physiology, molecular biology, and veterinary medicine, with an emphasis on porcine models that have implications for both agricultural science and human reproductive health. Dr. KACZMAREK serves as a peer reviewer for multiple prestigious journals including Biology of Reproduction, BMC Genomics, and Communications Biology, demonstrating her standing in the scientific community. She actively contributes to the advancement of reproductive science through her editorial work and research leadership.

• Biofuels
• Plant Biology
• C4 Photosynthesis
• +7 more

Professor Christopher Grof is an Honorary Professor in the School of Environmental and Life Sciences at the University of Newcastle, specializing in plant biology and biofuel research. His work focuses on enhancing biofuel production through genetic manipulation of plants like sorghum and sugarcane. Grof holds a PhD from James Cook University and previously served as a Principal Research Scientist at CSIRO Plant Industry. Research Interests: Biofuels, C4 photosynthesis, plant sugar transporters, cell wall construction, and microRNA pathways. Key Projects: Developing sorghum as a sustainable biofuel feedstock, improving carbohydrate metabolism in sugarcane, and analyzing plant responses to abiotic stress. Grants & Collaborations: Secured a $500,000 ARC grant for a specialized greenhouse and collaborates with institutions such as the University of Queensland and Texas A&M University. Awards: Recipient of the prestigious Underwood Fellowship from the British Biotechnology and Biological Sciences Council. His research emphasizes second-generation biofuels, leveraging genetic tools to optimize plant traits for biomass and sugar content. Grof’s work bridges fundamental biology with applied agriculture, aiming to reduce reliance on fossil fuels while supporting rural economies.

• Circadian Biology
• Clock Genes
• Addiction
• +3 more

Dr. Glenn Yamakawa is a Lecturer in Sleep and Circadian Biology at the School of Medical Sciences , University of Sydney , and a member of the Brain and Mind Centre . His research focuses on the intersection of circadian biology, traumatic brain injury, and neuroimmunology. Key Research Themes : Neurosciences and Mental Health, Healthy Ageing Dr. Yamakawa's recent work (2022-2024) explores circadian-immune system interactions, microbiome-gut-brain axis modulation, and biomarker development for post-traumatic epilepsy. His studies employ animal models and molecular/cellular approaches to investigate age-dependent responses, sex differences, and therapeutic interventions. Notable contributions include the 2024 Hidden Gem Award for leadership in circadian biology and the 2022 GIN Discovery Project Seed grant for cross-disciplinary neurotrauma research. He actively participates in the EpiBioS4Rx multisite study on post-traumatic epilepsy and contributes to preclinical MRI harmonization protocols. Dr. Yamakawa also teaches units on Brain and Behaviour , Sleep and Circadian Rhythms , and Sleep and Health .

Dongli LiuView profile

Research Fellow

• Cancer Cell Biology
• Cancer Therapy (excluding chemotherapy and radiation therapy)
• Bioinformatics and Computational Biology
• +5 more

Dr. Dongli Liu is a Research Fellow in the School of Clinical Medicine at the Lowy Cancer Research Centre , University of New South Wales (UNSW Sydney) . She specializes in gynaecologic oncology , focusing on ovarian cancer , endometrial cancer , and biomarker discovery through advanced preclinical models and next-generation sequencing (NGS) techniques. Grants: UNSW 3Rs Grant (2024), Endometriosis Australia Project Grant (2021), MAZDA Foundation Grant (2022), UNSW EMCR Seed Grant (2023), UNSW Medicine ECAN-Ramaciotti Centre ECR Grant (2022) Awards: WHRTN Emerging Leaders Fellowship (2025), ANZGOG Best Poster Award (2023), ANZGOG Abstract Award (2022), GEDDA Award (2017), Chinese Government Award (2016) Her research integrates molecular biology with bioinformatics , particularly through patient-derived primary cell culture and organoid models . Her recent publications analyze deep learning approaches for cancer cell identification, 2D/3D model comparisons , and ROR1/ROR2 targeting in gynaecological cancers. She currently supervises 3 postgraduate researchers (1 Honours, 2 PhD candidates).

Herbert M. LachmanView profile

Professor

• Molecular Genetics
• Neurodevelopmental Disorders
• Stem Cell Biology
• +4 more

Dr. Herbert M. Lachman is a Professor at the Albert Einstein College of Medicine, holding positions in the Departments of Psychiatry and Behavioral Sciences, Medicine (Oncology & Hematology), Neuroscience, and Genetics. A physician and behavioral geneticist, his research focuses on the molecular and genetic basis of schizophrenia, autism spectrum disorders, bipolar disorder, and intellectual disabilities. He employs induced pluripotent stem cell (iPSC) technology to model neuropsychiatric disorders, studying neurogenesis, gene expression, and environmental factors like immune system involvement in diseases such as PANS. Education & Clinical Background: M.D. from New York Medical College Fellowship at Montefiore Medical Center Residency at Metropolitan Hospital Research Interests: Dr. Lachman’s lab uses iPSC-derived neurons, cerebral organoids, and CRISPR-Cas9 gene editing to analyze schizophrenia, autism, and 22q11.2 deletion syndrome. Recent work explores environmental influences like pesticide exposure and immune dysfunction in neuropsychiatric disorders. Key areas include epigenetic analysis, transcriptomics, and proteomics in patient-specific models. Article Trends: Publications emphasize iPSC-derived models, CRISPR knockout studies of autism genes (e.g., CHD8), and the role of microglia in neurodevelopmental disorders. Recent work highlights Jansen de Vries Syndrome proteomics and PANS genetic variants. Grants & Awards: No awards listed, but his NIH-funded research includes collaborations on neurodevelopmental and psychiatric disorders. Advising details are unspecified. Labs & Teams: His lab collaborates across departments at Einstein, focusing on interdisciplinary approaches to neuropsychiatric disease modeling and genetic mechanisms.

Xin WangView profile

Associate Professor

• Synthetic Biology
• Cyanobacteria
• Photosynthesis
• +3 more

Xin Wang is an Associate Professor in the Department of Microbiology & Cell Science at the University of Florida. His research focuses on microbial physiology and synthetic biology, particularly exploring the design principles of cells and their applications. Key research interests include photosynthesis, cyanobacteria, and synthetic biology. His lab investigates mechanisms regulating gene expression, drug metabolism pathways, and pharmacogenomic markers influencing drug response. Dr. Wang’s work integrates genetic, epigenetic, and transcriptomic approaches to understand regulatory networks in human tissues, with applications in personalized medicine and drug development. The lab collaborates on projects addressing CYP enzyme regulation, miRNA biomarkers for therapeutic toxicity, and social determinants of health in chronic diseases. Lab Members: Postdoc Ningdong Xie; Graduate Students Nowshin Islam, Zhenxiong Jiang, Chetna Sharma Key Technologies: Allele-specific protein expression analysis, QconCAT proteomics, ChIP-seq Focus Areas: Pharmacogenomics, Enzyme Regulation, Microbial Engineering Publications highlight contributions to understanding genetic variants affecting drug metabolism, miRNA-driven pathways in cancer therapy, and regulatory mechanisms in liver and heart tissues. Ongoing work emphasizes translational applications of synthetic biology for biotechnology and medicine.